Literature DB >> 21099364

Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.

Stephen A Mihalcik1, Renee C Tschumper, Diane F Jelinek.   

Abstract

Together, circulating BAFF and dominant receptor BAFF-R homeostatically regulate the humoral immune system. Consistently aberrant BAFF-R expression in leukemic cells reveals an intimate connection of these cells' malignant physiology to the BAFF/BAFF-R axis and also provides an additional survival mechanism to the expressing cells. In this study, we used primary cells and cell lines to interrogate the mechanisms underlying aberrant BAFF-R expression in precursor B acute lymphoblastic leukemia (precursor B-ALL) and mature B chronic lymphocytic leukemia (CLL). Here we demonstrate the aberrant expression of BAFF-R in precursor B-ALL cell lines and reveal that these cells acquire BAFF-R expression through premature transcriptional activation of the BAFF-R promoter in coordination with regulatory transcription factor c-Rel. Investigations using primary CLL cells provide a crucial counterpoint through their paucity of BAFF-R relative to their benign mature B cell counterparts, which we establish as functionally significant in its depletion of the CLL cells' BAFF-binding capacity. Furthermore, BAFF-R downregulation in CLL patients is revealed here to be restricted to the malignant compartment and mediated post-transcriptionally in order to compensate for the consistently unchanged levels of transcription factor c-Rel and BAFF-R mRNA. Finally, we present evidence that CLL cells retain endogenous mechanisms of BAFF-R regulatory control despite active receptor dysregulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099364      PMCID: PMC3047811          DOI: 10.4161/cc.9.24.14156

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  22 in total

1.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

Authors:  Catherine Kern; Jean-Francois Cornuel; Christian Billard; Ruoping Tang; Danielle Rouillard; Virginie Stenou; Thierry Defrance; Florence Ajchenbaum-Cymbalista; Pierre-Yves Simonin; Sophie Feldblum; Jean-Pierre Kolb
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

2.  Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.

Authors:  Anne J Novak; Deanna M Grote; Steven C Ziesmer; Michael P Kline; Michelle K Manske; Susan Slager; Thomas E Witzig; Tait Shanafelt; Timothy G Call; Neil E Kay; Diane F Jelinek; James R Cerhan; Jane A Gross; Brandon Harder; Stacey R Dillon; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2006-01-23       Impact factor: 44.544

3.  BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.

Authors:  Javier Briones; John M Timmerman; David M Hilbert; Ronald Levy
Journal:  Exp Hematol       Date:  2002-02       Impact factor: 3.084

4.  Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

Authors:  Soon-Min Tan; Dong Xu; Viktor Roschke; James W Perry; Daniel G Arkfeld; Glenn R Ehresmann; Thi-Sau Migone; David M Hilbert; William Stohl
Journal:  Arthritis Rheum       Date:  2003-04

5.  Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

Authors:  G S Cheema; V Roschke; D M Hilbert; W Stohl
Journal:  Arthritis Rheum       Date:  2001-06

6.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.

Authors:  J Zhang; V Roschke; K P Baker; Z Wang; G S Alarcón; B J Fessler; H Bastian; R P Kimberly; T Zhou
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

9.  Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.

Authors:  Anne J Novak; Richard J Bram; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

10.  The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome.

Authors:  X Mariette; S Roux; J Zhang; D Bengoufa; F Lavie; T Zhou; R Kimberly
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

View more
  8 in total

1.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

2.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

Review 3.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

4.  Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway.

Authors:  Eugenio Mora; Angelo Guglielmotti; Giuseppe Biondi; Paolo Sassone-Corsi
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

5.  Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Authors:  R Parameswaran; M Yu; M-A Lyu; M Lim; M G Rosenblum; J Groffen; N Heisterkamp
Journal:  Leukemia       Date:  2012-02-29       Impact factor: 11.528

6.  TACI expression and signaling in chronic lymphocytic leukemia.

Authors:  Antigoni Mamara; Anastasios E Germenis; Maria Kompoti; Maria Palassopoulou; Eudokia Mandala; Anastasia Banti; Nikolaos Giannakoulas; Matthaios Speletas
Journal:  J Immunol Res       Date:  2015-04-09       Impact factor: 4.818

7.  TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss.

Authors:  Guangchao Li; Qing Zhang; Zhi Liu; Huijuan Shen; Yangmin Zhu; Zhao Zhou; Wen Ding; Siqi Han; Jie Zhou; Ruiming Ou; Min Luo; Shuang Liu
Journal:  Cancer Cell Int       Date:  2021-04-17       Impact factor: 5.722

8.  Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course.

Authors:  Kim L Clar; Lisa M Weber; Bastian J Schmied; Jonas S Heitmann; Maddalena Marconato; Claudia Tandler; Pascal Schneider; Helmut R Salih
Journal:  Cancers (Basel)       Date:  2021-12-04       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.